People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CARISMA Therapeutics Inc. | — | Biotechnology | Series C | $95.0M | $1.3B | 2017 |
| Pinteon Therapeutics, Inc. | — | Biotechnology | Series B | $39.2M | $603.8M | 2014 |
| Better Life Partners Inc. | — | Other Health Care | Series B | $33.9M | $232.0M | 2020 |
| Artelo Biosciences, Inc. | — | Biotechnology | Series A | $23.2M | $723K | 2017 |
Steven Kelly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Kelly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Liam Donohue | 1 | 12 |
| Jon Lim | 1 | 9 |
| Jason Dinges | 1 | 8 |
| Briggs Morrison | 1 | 8 |
| Stephanie O'Brien | 1 | 7 |
| Bruce Peacock | 1 | 5 |
| Michael Heffernan | 1 | 5 |
| Michael Poisel | 1 | 4 |
| Eran Nadav | 1 | 4 |
| Margarita Chavez | 1 | 4 |
| Yair Schindel | 1 | 4 |
| Chidozie Ugwumba | 1 | 3 |
| Jeffrey L. Ives | 1 | 3 |
| Peter O'Brien | 1 | 3 |
| Regina Hodits | 1 | 2 |
| Gregory D. Gorgas | 1 | 2 |
| Mark R. Spring | 1 | 2 |
| R. Martin Emanuele | 1 | 2 |
| Adam Groff | 1 | 2 |
| Althea Stillman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.